Abstract
Establishing the most effective route to exit for a biotech venture is
critical in ensuring value is maximized for key stakeholders and the
associated technology. However, more critical than selection of exit strategy
is the planning and effective execution of exit. Fledgling biotech companies
owe their existence to the promise of a valuable exit for the early-stage
funder. As a result, each and every biotech company must be able to
demonstrate that all plans and actions are effective steps towards the
realization of success exit, even where the method and timing of exit are
largely undecided. - Biotech Exit Strategies - report provides a detailed
review of current and future trends in biotech exit strategies and uses
real-life case studies to illustrate the key challenges and critical success
factors involved in executing an exit for biotech investors. The report
provides a unique strategic analysis for successfully dealing with the
prevailing challenging financial conditions facing biotech companies and
investors.
|